Dejo información esperanzadora, que he encontrado en http://lacartadelabolsa.com/leer/articulo/julius_baer_comentarios_actualidad1
EQUITIES: Hillary Clinton’s proposals on US drug pricing are neither new nor easily achievable
Several proposals stated earlier this week by Hillary Clinton would not have a major impact on the healthcare industry: 1) stopping direct to consumer advertising,
2) capping out-of-pocket costs to USD 250 per month on prescription drugs for chronic or serious health conditions. The current average co-pay is USD500 per year, thus not many will benefit.
3) Reducing the exclusivity of specialty drugs from 12 to 7 years. However these products are protected by patents that already now determine the entry of competition.
4) Allow drug imports. This has strongly been opposed by the Food and Drug Administration (FDA) as quality would be hard to be assessed.
5) Clear out the FDA generic backlog. This is already happening. The issue that impacted the valuation of pharma and biotech stocks was: 1) Allow Medicare to negotiate drug and biologic prices. Medicare already has significant rebates; however group purchasing could lead to lower pricing. For the implementation of Medicare negotiations on drug prices, Ms Clinton first has to win the election and get this through a Congress with Republican majority. We this see this change unlikely in the medium term.
We see the current correction as an entry point into high-quality biotech and pharma names.
Lilian Montero, Equity Analyst, Julius Baer
Saludos